Company / Return on Equity (ROE)
Tonix Pharmaceuticals Holding Corp. Return on Equity (ROE) History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-93.2%
FY2025
5-year range
-110.5% / -53.2%
FY2023-FY2025
Trend
+15.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Tonix Pharmaceuticals Holding Corp. reports negative total equity of -93.2% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-93.2% in FY2025.
Declined from -53.2% to -93.2% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 15.7% year-over-year.
Company context
Key Data Points
- Altman Z-Score -0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -93.2% | +15.7% |
| FY2024 | -110.5% | -107.8% |
| FY2023 | -53.2% | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 28, 2026